Cost-Effectiveness Comparison of Genotype 1 Hepatitis C Virus (HCV) Treatments Using Telaprevir (TVR) in Patients with Mild Fibrosis Versus Patients with Bridging Fibrosis and Cirrhosis
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.189
https://www.valueinhealthjournal.com/article/S1098-3015(13)02094-9/fulltext
Title :
Cost-Effectiveness Comparison of Genotype 1 Hepatitis C Virus (HCV) Treatments Using Telaprevir (TVR) in Patients with Mild Fibrosis Versus Patients with Bridging Fibrosis and Cirrhosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02094-9&doi=10.1016/j.jval.2013.08.189
First page :
A354
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
175